FTC, Four States Sue WPATH Over Claims On Youth Gender Treatments
The Federal Trade Commission and the states of Alaska, Iowa, Nebraska and Texas sued the World Professional Association for Transgender Health on Wednesday, June 17, 2026, accusing it of misleading parents about youth gender treatments.[1]
The complaint says WPATH made deceptive claims about puberty blockers, cross-sex hormones and surgeries for minors and removed age-based recommendations from its standards of care.[1] FTC Chair Andrew Ferguson framed the case as protecting parents from deception, while WPATH called the action retaliatory and said its standards support individualized treatment.[1]
On January 15, 2026, the FTC issued a Civil Investigative Demand to WPATH as part of an inquiry into whether the group had made or aided false or unsubstantiated claims about treatments for minors. WPATH petitioned to quash the demand on February 9 and filed suit in D.C. federal court on February 18 to block enforcement on First Amendment and jurisdiction grounds. A federal judge granted WPATH a preliminary injunction on May 7 that temporarily halted the agency's inquiry.
The FTC had hosted a July 9, 2025 workshop examining potential deceptive trade practices in gender-affirming care for minors. Analysis of private insurance claims from 2018 to 2022 found 926 adolescents received puberty blockers and 1,927 received cross-sex hormones among more than 5.1 million adolescents ages 8-17. The case has drawn sharp social-media reactions, with supporters praising the suit as accountability and critics calling it retaliatory.
The mainstream summary does not mention the broader context of institutional trust issues surrounding medical organizations like WPATH, which have faced scrutiny for allegedly suppressing systematic reviews that question the efficacy and safety of treatments for gender dysphoria in minors. A 2025 U.S. Department of Health and Human Services report highlighted significant long-term harms associated with puberty blockers and cross-sex hormones, emphasizing that these interventions were inadequately tracked. This perspective contrasts with the FTC's framing of the lawsuit as merely a protective measure for parents, suggesting a deeper systemic concern regarding the standards set by WPATH and their implications for youth care.
Additionally, while the mainstream account provides statistics on the number of adolescents receiving treatments, it does not address the low certainty of the evidence supporting these interventions, as noted in the 2024 Cass Review. This review led to significant policy changes in several European countries, which have opted to restrict the use of puberty blockers outside of research settings due to similar findings. Such critical insights highlight the complexities and controversies surrounding youth gender treatments that the mainstream summary overlooks, suggesting that the legal actions against WPATH are part of a larger debate about the validity and safety of these medical practices.[2]
Show source details & analysis (1 source)
📊 Relevant Data
A JAMA Pediatrics analysis of U.S. private insurance claims data covering more than 5.1 million adolescents ages 8-17 found that 926 received puberty blockers and 1,927 received cross-sex hormones between 2018 and 2022.
Gender-Affirming Medications Among Transgender and Gender-Diverse Adolescents — JAMA Pediatrics
📌 Key Facts
- On Wednesday, June 17, 2026, the FTC and the states of Alaska, Iowa, Nebraska and Texas filed a lawsuit against WPATH.
- The complaint alleges WPATH made deceptive claims about puberty blockers, cross-sex hormones and surgeries for minors and removed age-based recommendations from its standards of care.
- FTC Chair Andrew Ferguson publicly framed the case as protecting parents from deception, while WPATH called the action retaliatory and said its standards support individualized treatment.
📰 Source Timeline (1)
Follow how coverage of this story developed over time